Patents Assigned to MEDIMMUNE LIMTIED
  • Combination therapy with an anti-axl antibody-drug conjugate
    Patent number: 10544223
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 28, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMTIED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi